期刊文献+

糖足颗粒剂外用对神经性糖尿病足大鼠模型的影响 被引量:3

Effect of Tangzu Granules with External Application on Neuropathic Diabetic Foot Model Animals
暂未订购
导出
摘要 目的:观察糖足颗粒剂对神经性糖尿病足动物模型的影响,评价该中药复方的药效动力学。方法:将60只雄性SD大鼠随机分为正常对照组,模型对照组,蒸馏水组,糖足颗粒剂高、中、低剂量组6组,每组各10只。STZ造模成功后,钳夹坐骨神经以制成神经性糖尿病足动物模型。糖足颗粒剂高、中、低剂量组每日给药量为4.08,2.04,1.02μg/g。体质量,用温蒸馏水12.5×10-3 L(37~40℃)溶解后备用。将糖足颗粒剂均匀涂布于大鼠左侧大腿裸露皮肤上,用纱布包裹并用无刺激医用胶布固定,接触1 h后洗净。蒸馏水组同法给予等量等温蒸馏水。正常对照组、模型对照组不予任何处理。每天给药1 h,持续30 d。分别于术后第1,2,4周检测大鼠坐骨神经功能指数(SFI);术后4周,处死大鼠,对比手术侧与正常侧腓肠肌湿重,计算恢复率;光镜下观察术侧腓肠肌细胞生长情况、坐骨神经纵切面轴突再生和髓鞘形成情况,采用软件分析肌细胞的直径、轴突面积、髓鞘面积。结果:大鼠坐骨神经功能指数测定显示,糖足颗粒剂治疗组的SFI分别与蒸馏水组对比,差别无统计学意义(P>0.05);糖足颗粒剂组之间对比,无明显差别(P>0.05)。坐骨神经髓鞘、轴突面积,糖足颗粒剂治疗组与蒸馏水组对比、糖足颗粒剂组之间对比,髓鞘面积总和和轴突面积总和差别均不大(P>0.05)。各组腓肠肌湿重恢复率,糖足颗粒剂治疗组与蒸馏水组对比,差别有统计学意义(P<0.05);糖足颗粒剂组内的恢复率,与糖足颗粒剂高剂量组对比,有统计学意义(P<0.05),与糖足颗粒剂中剂量组对比,差别无统计学意义(P>0.05)。腓肠肌细胞直径,糖足颗粒剂治疗组与蒸馏水组对比,差别有统计学意义(P<0.05);糖足颗粒剂组之间,与糖足颗粒剂高剂量组对比,差别无统计学意义(P>0.05);与糖足颗粒中剂量组对比,糖足颗粒低剂量组肌细胞直径无显著增加,差别无统计学意义(P>0.05)。结论:经过糖足颗粒剂的治疗,神经性糖尿病足大鼠足趾外观有所好转,腓肠肌肌细胞形态恢复明显;但在坐骨神经功能和坐骨神经组织学观察上,糖足颗粒剂治疗组的恢复与对照组无明显差别。
出处 《中医研究》 2018年第6期64-68,共5页 Traditional Chinese Medicinal Research
基金 四川省干保科研课题(H2017033) 成都中医药大学附属医院基金(2016-D-YY-01)
  • 相关文献

参考文献4

二级参考文献21

  • 1李晓玲,朱旅云,葛秀兰,王广宇,胡丽叶.血清基质金属蛋白酶9及其抑制物1与糖尿病视网膜病变的关系[J].临床内科杂志,2005,22(9):592-594. 被引量:4
  • 2Noda K, Inoue M, Ishida S, Obata K, Oquchi Y, Okada Y, et al. Production and activition of matrix metalloproteinase-2 in pro- lfferative diabetic retinopathy [ J ]. Invest Ophthalmol Vis Sci, 2003,44(5) :2153-2170.
  • 3Ferrara N. Vascular endothelial growth factor:basic since and clinical progress [ J ]. Endocr Rev, 2004,25 ( 4 ) : 581-511.
  • 4Sarlos S, Rizlalla B, Moravski C J, Cao Z, Cooper ME, Wilkinson-Berka JL. Retinal angiogenesis is mediated by an interaction be- tween the angiotensin type 2 receptor, VEGF, and angiopoietin [ J]. Am J Pathol,2003,163 ( 8 ) :879-877.
  • 5Nambu H, Namr R, Oshima Y, Hackett SF, Okoye G, Wieqand S, et al. Angiietin I inhhibits ocular neovescularization and break- down of the blood-retinal barrier [J]. Gene Ther, 2004,11 ( 10 ) : 865 -873.
  • 6De La Paz MA, Itoh CA, Itoh CA, Naqase H. Matrix metallopro- teinases and their inhibitors in human vitreous[J]. Invest Oph- thalmol Vis Sci,1998,39(7) :1255-1250.
  • 7Kowluru RA, Kanwar M. Oxidative stress and the development of diabetic retinopathy: contributory role of matrix metallopro- teinase-2[J]. Free Radic Biol Med ,2009,45 ( 12 ) : 1577-1585.
  • 8Beranek M, Kolar P, Tschoplova S, Kankova K,Vasku A. Genetic variations and plasma levels of gelatinase A( matrix metallopro- teinase-2 ) and gelatinase B ( matrix metalloproteinase-9 ) in pro- liferative diabetic retinopathy [J]. Mol Vis ,2008,14 : 1114-1121.
  • 9Giebel S J, Meicucci G, McGuire PG, Da SA. Matrix metallopro- teinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier [ J ]. Lab Invest, 2005,85 ( 5 ) : 597- 607.
  • 10Jacqueminet S, Ben Abdesselam O, Chapman M J, Nicolay N, Fo- glietti M J, Grimaldi A, et al. Elevated circulating levels of matrix metalloprotcinase-9 in type 1 diabetic patients with and without retinopathy [J]. Clin Chim Aca ,2006,367 ( 1-2 ) : 103-107.

共引文献6992

同被引文献49

引证文献3

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部